Clinical Trials Logo
  1. Home
  2. Neoplasms, Colorectal
  3. NCT00540943

Study of Pazopanib, Irinotecan and Cetuximab in Combination to Treat 2nd Line Metastatic Colorectal Cancer

Neoplasms, Colorectal Clinical Trial

Official title:
Phase I Study of Safety and Pharmacokinetics of Pazopanib in Combination With Cetuximab and Irinotecan in Patients With Colorectal Cancer

Clinical Trial Summary

Subjects will be entered into cohorts of 3 for the dose escalation phase so that the maximum tolerated dose can be determined. 18 additional patients will be recruited once the maximum tolerated dose (MTD) is determined for disease assessment.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00540943
Study type Interventional
Source GlaxoSmithKline
Contact
Status Completed
Phase Phase 1
Start date July 13, 2007
Completion date May 3, 2010
View Details
See also
  Status Clinical Trial Phase
Completed NCT00536809 - Phase I/II Study of Lapatinib in Combination With Oxaliplatin and Capecitabine in Subjects With Advanced Colorectal Cancer Phase 1
Active, not recruiting NCT02395224 - A Longitudinal Study of Colorectal Cancer Patients With Metastatic Disease in Middle-Norway
Completed NCT00967616 - Study of CS-7017 in Combination With FOLFIRI in Subjects With Metastatic Colorectal Cancer Who Failed First-Line Therapy Phase 2
Completed NCT00704600 - Nelfinavir, a Phase I/Phase II Rectal Cancer Study Phase 1/Phase 2
Recruiting NCT05358249 - Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation Phase 1/Phase 2
Terminated NCT01545141 - Chemokine-Modulatory Regimen for Recurrent Resectable Colorectal Cancer Phase 1/Phase 2
Withdrawn NCT01157039 - A Trial of Glutamine to Prevent Oxaliplatin Neurotoxicity and a Pharmacokinetic Analysis of Oxaliplatin Phase 2
Completed NCT00387387 - Study On Pazopanib When Given With FOLFOX6 (Fluorouracil, Oxaliplatin, Leucovorin) Or CapeOx (Capecitabine, Oxaliplatin) Phase 1
Completed NCT03428958 - A Safety, Pharmacokinetic and Efficacy Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment Phase 1/Phase 2
Recruiting NCT04593407 - Endoscopic Mucosal Resection Versus Endoscopic Submucosal Dissection for Colorectal Laterally Spreading Lesions. N/A
Completed NCT00478634 - A Phase 1 Study Investigating the Combination of RAD001, Cetuximab and Irinotecan as Second-line Therapy After FOLFOX (or XELOX) Plus Bevacizumab in Patients With Metastatic Colorectal Cancer Phase 1
Active, not recruiting NCT03885817 - Physically Active During Cancer Treatment (FAKT) N/A
Completed NCT01139138 - Safety Study of the Combination of Panitumumab, Irinotecan and Everolimus in the Treatment of Advanced Colorectal Cancer Phase 1/Phase 2
Completed NCT06118125 - Delay to Diagnosis in Digestive Cancerology by the General Practitioner Related to Covid-19 Pandemic Confinement
Not yet recruiting NCT01157052 - Oxaliplatin Pharmacokinetics With and Without Ca2+/MG2+ Infusion in Colorectal Cancer Patients Phase 1
Completed NCT01671592 - Safety of Labeled Dendritic Cell (DC) Vaccines and Feasibility of Tracking by Magnetic Resonance Imaging (MRI) Phase 1
Completed NCT02321969 - Green Tea Extracts for the Prevention of Colorectal Adenomas and Colorectal Cancer N/A
Completed NCT00920803 - A Clinical Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of SRT501 in Subjects With Colorectal Cancer and Hepatic Metastases Phase 1